Novavax to Participate in BofA Securities 2024 Health Care Conference
GAITHERSBURG, Md., May 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the BofA Securities 2024 Health Care Conference.
Conference Details: |
||||||
Fireside Chat |
||||||
Date: |
Wednesday, May 15, 2024 |
|||||
Time: |
3:00 – 3:30 p.m. Pacific Daylight Time (PDT) |
|||||
Location: |
Encore Hotel in Las Vegas, NV |
|||||
Moderator: |
Alec Stranahan, PhD, Equity Research – U.S. Biopharma |
|||||
Novavax participant: |
John C. Jacobs, President and Chief Executive Officer |
|||||
Conference |
||||||
Event: |
Investor Meetings |
|||||
Date: |
Wednesday, May 15, 2024 |
|||||
Recordings
A replay of the recorded fireside session will be available through the Events & Presentations page of the Company's website at ir.novavax.com for 30 days from the date of the conference.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Erika Schultz
240-268-2022
[email protected]
Media
Giovanna Chandler
202-709-5563
[email protected]
SOURCE Novavax, Inc.
Share this article